Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Abbott Diagnostics Resource Report Resource Website 10000+ mentions |
Abbott Diagnostics (RRID:SCR_008392) | Abbott | commercial organization | Company offering a broad range of instrument systems and diagnostic tests for hospitals, reference labs, blood banks, physician offices and clinics to aid in the diagnosis of a range of serious health issues such as infectious diseases, cancer, and diabetes, as well as monitor other important indicators of health. | diagnostic, medical device, instrument, reagent, infectious disease, cancer, diabetes, monitor, health, immunoassay, clinical chemistry, hematology, in vitro, diagnostics |
is related to: Towards novel translational safety biomarkers for adverse drug toxicity is related to: MIP-DILI is related to: NEWMEDS |
nif-0000-30049 | SCR_008392 | 2026-08-29 11:23:30 | 12644 | |||||||||
|
Towards novel translational safety biomarkers for adverse drug toxicity Resource Report Resource Website |
Towards novel translational safety biomarkers for adverse drug toxicity (RRID:SCR_004006) | ADR Research, | consortium, data or information resource, organization portal, portal | Consortium to develop novel in vitro predictive screening tools and in vivo translational models and biomarkers to improve adverse drug reaction (ADR) hazard identification. This project studies the metabolic effects of eight drugs (among which are paracetamol and diclofenac ) with known side effects in the liver. By looking into the mechanics on a level ranging from the molecule to the patient, the researchers in this project aim to find biomarkers and develop tools for the early prediction of side effects of drugs. One of the breakthroughs in the project is the discovery that a person''''s genetic profile appears to be one of the mechanics that have an influence on the resistance to adverse drug reactions. The ability to identify adverse effects in an early stage will prevent much discomfort in patients and economic loss. Several PhD theses have been written from this project. | biomarker, drug development, adverse drug reaction, in vitro, in vivo, screening tool, translational model, drug, liver, side effect, thesis, paracetamol, diclofenac, genetic profile, gene, safety |
is listed by: Consortia-pedia is related to: Abbott Diagnostics has parent organization: TI Pharma |
nlx_158422 | SCR_004006 | ADR Safety Biomarkers, Adverse Drug Reaction Research | 2026-08-29 11:27:43 | 0 | ||||||||
|
MIP-DILI Resource Report Resource Website 1+ mentions |
MIP-DILI (RRID:SCR_003870) | MIP-DILI | consortium, data or information resource, organization portal, portal | Consortium that brings together Europe's top industrial and academic experts to develop new tests that will help researchers detect potential liver toxicity issues much earlier in drug development, saving many patients from the trauma of liver failure. The team aims to deepen the understanding of the science behind drug-induced liver injury, and use that knowledge to overcome the many drawbacks of the tests currently used. A major focus will be on a systematic and evidence-based evaluation of both currently available and new laboratory test systems, including cultures of liver cells in one-dimensional and three dimensional configurations. The project will also develop models that take into account the natural differences between patients. This is important because factors such as certain genes, the liver's immune response, and viral infections have all been associated with an increased risk of DILI. The project will seek to address the current lack of human liver cells available to researchers by using induced pluripotent stem cells (iPSCs) generated from patients who are particularly sensitive to DILI. Another strand of the project will develop computer models to unravel the complex, often inter-related mechanisms behind DILI. Finally, the team will assess how accurate the results of laboratory tests are at predicting actual outcomes in patients. | drug, liver, toxicity test, toxicity, drug development, tool development, liver toxicity, preclinical, model, induced pluripotent stem cell, liver cell, gene, immune response, computer model, outcome |
is listed by: Consortia-pedia is related to: Abbott Diagnostics is related to: Janssen Research and Development is related to: Merck is related to: Orion is related to: University of Liverpool; Liverpool; United Kingdom is related to: University of Freiburg; Baden-Wurttemberg; Germany is related to: German Cancer Research Center is related to: Karolinska Institute; Stockholm; Sweden is related to: University of Rennes 1; Rennes; France is related to: Leiden University; Leiden; Netherlands is related to: Utrecht University; Utrecht; Netherlands is related to: VU University; Amsterdam; Netherlands is related to: Cellartis is related to: CXR Biosciences is related to: Interface Europe is related to: KaLy-Cell is related to: Lhasa Limited is related to: SOLVO Biotechnology has parent organization: Interface Europe |
Innovative Medicines Initiative 115336; EFPIA |
nlx_158195 | SCR_003870 | Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI), Mechanism based Integrated systems for the Prediction of Drug Induced Liver Injury, Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury | 2026-08-29 11:21:41 | 2 | |||||||
|
NEWMEDS Resource Report Resource Website 1+ mentions |
NEWMEDS (RRID:SCR_003872) | NEWMEDS | consortium, data or information resource, organization portal, portal | Consortium that will develop new models and methods to enable novel treatments for schizophrenia and depression including three important missing tools that will facilitate the translation of scientific findings into benefits for patients. The project will focus on developing new animal models which use brain recording and behavioral tests to identify innovative and effective drugs for schizophrenia. The project will develop standardized paradigms, acquisition and analysis techniques to apply brain imaging, especially fMRI and PET imaging to drug development. It will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it will try and develop new approaches for shorter and more efficient trials of new medication - trials that may require fewer patients and give faster results. | drug, biomarker, neuroimaging, drug development, tool development, animal model, fmri, pet, gene, medicine, clinical trial, genetic variation, molecule, model, dna, protein |
is listed by: Consortia-pedia is related to: Abbott Diagnostics is related to: Janssen Research and Development is related to: Orion is related to: Pfizer Animal Genetics is related to: Roche is related to: King's College London; London; United Kingdom is related to: Karolinska Institute; Stockholm; Sweden is related to: University of Cambridge; Cambridge; United Kingdom is related to: Central Institute of Mental Health; Mannheim; Germany is related to: Spanish National Research Council; Madrid; Spain is related to: University of Manchester; Manchester; United Kingdom is related to: Bar-Ilan University; Ramat Gan; Isreal is related to: Psynova Neurotech is related to: deCODE genetics is related to: GABO:mi is related to: AbbVie has parent organization: King's College London; London; United Kingdom is parent organization of: DepressionTools.org Clinical Significance Calculator is parent organization of: Pharmacological Imaging and Pattern Recognition toolbox is parent organization of: DUPCheck |
Innovative Medicines Initiative 115008; EFPIA |
nlx_158196 | SCR_003872 | Novel Methods leading to New Medications in Depression and Schizophrenia, NEWMEDS - Novel Methods leading to New Medications in Depression and Schizophrenia | 2026-08-29 11:22:01 | 6 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.